MinervaX
MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus (GBS). The lead candidate, AlpN GBS, is currently in clinical trials to prevent adverse pregnancy outcomes and life-threatening infections. The company specifically targets pregnant women and older adults to address unmet medical needs in these populations.
Biotech
Healthtech
Pharmaceuticals
Funding summary
- Total raised
- €177.8M
- Funding rounds
- 5
Investors in MinervaX
Investors on record for MinervaX. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like MinervaX?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors